Profile data is unavailable for this security.
About the company
Hamlet BioPharma AB, formerly Hamlet Pharma AB, is a Sweden-based pharmaceutical company that develops new drugs for the treatment and prevention of cancer. The Company provides new therapeutic solutions using a peptide-based molecular approach for targeting and killing tumour cells with greater precision. Its synthetic drug candidate Alpha1H kills tumor cells quickly, both in the laboratory and in animal models and in treated patients, where the response can be measured already within a few hours. The other product BAMLET kills cancer cells and has shown effects against growing tumor tissue, especially for colon cancer. Hamlet Pharma is therefore driving the development of BAMLET as a future drug against cancer. The Company intends to establish production of BAMLET primarily for clinical studies of the treatment/prevention of colon cancer in the gastrointestinal tract and oral cancer in the oral cavity.
- Revenue in SEK (TTM)0.00
- Net income in SEK-26.59m
- Incorporated1999
- Employees7.00
- LocationHamlet BioPharma ABKlinikgatan 32LUND 222 42SwedenSWE
- Phone+46 40122500
- Websitehttps://hamletbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intervacc AB | 8.02m | -102.85m | 340.06m | 15.00 | -- | 1.43 | -- | 42.43 | -1.47 | -1.47 | 0.1167 | 3.14 | 0.0306 | 3.08 | 1.72 | 534,333.30 | -39.21 | -17.62 | -42.12 | -18.77 | -628.60 | -243.59 | -1,283.24 | -626.90 | 4.38 | -- | 0.0006 | -- | -17.23 | -25.79 | -60.31 | -- | -38.72 | -- |
| Magle Chemoswed Holding AB | 170.01m | 12.23m | 349.92m | 78.00 | 28.61 | 2.17 | 13.97 | 2.06 | 1.13 | 1.13 | 15.74 | 14.95 | 0.6068 | 0.493 | 8.30 | 2,179,628.00 | 4.36 | 2.52 | 5.86 | 3.52 | 90.58 | 85.67 | 7.19 | 3.92 | 0.6356 | 6.35 | 0.3081 | -- | 17.00 | 9.97 | 33.07 | -- | -6.34 | -- |
| Lifecare ASA | 13.10m | -35.30m | 417.88m | 32.00 | -- | 6.29 | -- | 31.90 | -0.2903 | -0.2903 | 0.1088 | 0.4924 | 0.1621 | -- | 4.90 | 408,943.10 | -43.60 | -40.00 | -49.97 | -45.26 | -- | -- | -269.03 | -175.53 | -- | -- | 0.1812 | -- | -40.88 | 30.29 | -101.74 | -- | -- | -- |
| INIFY Laboratories AB | 3.42m | -51.38m | 426.97m | 23.00 | -- | 5.84 | -- | 124.90 | -1.13 | -1.13 | 0.0755 | 1.61 | 0.032 | 2.99 | 0.6608 | -- | -48.10 | -- | -48.10 | -- | 76.42 | -- | -1,503.10 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Mendus AB (publ) | 0.00 | -101.62m | 452.23m | 30.00 | -- | 0.5499 | -- | -- | -0.2554 | -0.2554 | 0.00 | 0.8165 | 0.00 | -- | -- | 0.00 | -14.77 | -18.84 | -15.78 | -20.21 | -- | -- | -- | -28,474.53 | -- | -- | 0.0325 | -- | -100.00 | -- | 26.78 | -- | -- | -- |
| Initiator Pharma A/S | 0.00 | -35.69m | 478.89m | 2.00 | -- | 27.27 | -- | -- | -0.6567 | -0.6567 | 0.00 | 0.3319 | 0.00 | -- | -- | 0.00 | -58.55 | -65.10 | -62.50 | -70.59 | -- | -- | -- | -- | -- | -- | 0.5804 | -- | -- | -- | 40.52 | -- | -- | -- |
| Promimic AB | 37.07m | -9.22m | 481.36m | 17.00 | -- | 6.27 | -- | 12.99 | -0.5283 | -0.5283 | 2.08 | 4.11 | 0.3994 | -5.63 | 3.00 | 2,180,588.00 | -9.93 | -24.89 | -11.67 | -29.25 | 103.90 | 101.23 | -24.88 | -89.47 | 3.98 | -- | 0.00 | -- | 128.63 | -- | 41.95 | -- | -- | -- |
| Bergenbio ASA | 354.40k | -190.62m | 511.05m | 18.00 | -- | 2.75 | -- | 1,442.03 | -0.2647 | -0.2647 | 0.0002 | 0.0474 | 0.0021 | -- | -- | -- | -111.66 | -66.15 | -176.09 | -78.74 | -- | -- | -53,785.59 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
| Hamlet BioPharma AB | 0.00 | -26.59m | 520.00m | 7.00 | -- | 11.49 | -- | -- | -0.207 | -0.207 | 0.00 | 0.3543 | 0.00 | -- | -- | -- | -63.29 | -83.52 | -69.05 | -107.84 | -- | -- | -- | -- | -- | -- | 0.0984 | -- | -- | -- | -18.87 | -- | 78.01 | -- |
| Enzymatica AB (publ) | 47.29m | -53.67m | 554.82m | 18.00 | -- | 6.61 | -- | 11.73 | -0.3247 | -0.3247 | 0.2866 | 0.4841 | 0.3269 | 1.38 | 6.48 | -- | -37.11 | -27.36 | -39.16 | -33.98 | 64.25 | 65.08 | -113.50 | -66.12 | -- | -23.26 | 0.2502 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| Gentian Diagnostics ASA | 142.38m | -5.84m | 586.71m | 58.00 | -- | 3.87 | 163.70 | 4.12 | -0.3783 | -0.3783 | 9.22 | 9.82 | 0.7646 | 1.85 | 6.35 | 2,452,035.00 | -3.14 | -10.76 | -3.58 | -11.86 | 50.84 | 41.46 | -4.10 | -26.99 | 4.14 | -- | 0.0555 | -- | 32.98 | 27.63 | 54.92 | -- | -4.92 | -- |
| Oncopeptides AB | 35.22m | -249.11m | 610.92m | 57.00 | -- | 6.47 | -- | 17.35 | -1.96 | -1.96 | 0.2776 | 0.4474 | 0.1129 | -- | 1.44 | 617,894.80 | -79.88 | -141.28 | -101.04 | -200.49 | 103.06 | -- | -707.30 | -2,689.06 | -- | -- | 0.7065 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
| Cantargia AB | 0.00 | -280.03m | 671.56m | 22.00 | -- | 3.98 | -- | -- | -1.65 | -1.65 | 0.00 | 0.9186 | 0.00 | -- | -- | 0.00 | -80.18 | -55.08 | -100.27 | -61.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.69 | -- | -- | -- |
| Intellego Technologies AB | 186.49m | 59.60m | 691.76m | 62.00 | 11.26 | 4.57 | 10.96 | 3.71 | 2.33 | 2.33 | 7.35 | 5.74 | 0.8841 | 3.87 | 3.69 | 3,007,968.00 | 28.26 | -- | 44.00 | -- | 68.73 | -- | 31.96 | -- | 2.07 | 5.82 | 0.1684 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
| Alligator Bioscience AB | 55.49m | -248.80m | 692.09m | 55.00 | -- | -- | -- | 12.47 | -0.4848 | -0.4848 | 0.0999 | -0.0772 | 0.5289 | -- | 8.07 | 956,741.40 | -237.13 | -73.26 | -- | -91.33 | -- | -- | -448.35 | -811.68 | -- | -104.20 | -- | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
Data as of May 16 2024. Currency figures normalised to Hamlet BioPharma AB's reporting currency: Swedish Krona SEK
